As we move into the final quarter of 2018, we reflect on a year with a strong IPO market that has created a hefty appetite for alliances, a bevy of notable M&A deals, a corporate tax reform package that has encouraged deal-making, and a biotech patent cliff that is driving even more companies to seriously pursue partnerships to bolster their portfolios. At the center of these trends lies the importance of identifying the right prospective partners for your next investment or licensing deal, and no other system facilitates this process like BIO One-on-One Partnering™.
The 18th Annual BIO Investor Forum is less than a month away, and this cornerstone investor conference is slated to deliver a compelling combination of partnering meetings, educational sessions on the industry’s most popular topics, and company presentations featuring innovative public and venture-stage companies.
Taking place October 17-18 in San Francisco, the BIO Investor Forum is a signature venue for connecting investors with business development leaders and senior management from emerging biotechnology companies.
Attendees can take advantage of the BIO One-on-One Partnering™ system to review detailed company and investor profiles; search by therapeutic area, geography, and company size; and schedule face-to-face meetings with the movers and shakers driving the deals that are transforming our industry.
New this year, meeting requests can be made from the One-on-One mobile app, companies can be filtered by their in-licensing and out-licensing goals, and resources like pitch decks and one-pagers can be linked to specific meeting requests with companies to better showcase an offering.
Meeting scheduling will begin in early October, so there is still time to register for the conference! With the highest growth rate in scheduled partnering meetings among BIO’s global portfolio of partnering events, the BIO Investor Forum is the preeminent autumn event to explore investment opportunities in the life sciences.
Be sure to RSVP for our September 25 webinar, “Expert Perspectives on Investigational PD-1 Combination Therapies in I/O,” which complements the Wednesday panel on navigating checkpoint inhibitors’ clinical results. If you will be continuing your partnering activities during JPM Week in January, please join our BIO One-on-One Partnering @ JPM Week Info Session on Wednesday at 2:30 PM during the BIO Investor Forum.
We hope to see you in San Francisco!